Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission
Inflammatory Bowel Diseases · 01.09.2025 · 31 (9) · 2511-2520
DOI: 10.1093/ibd/izaf043 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 11.03.2025. Verfasst von Katie A Dunleavy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Intestinal Mucosa, Crohn Disease, Colitis, Ulcerative, Intestine, Small. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Department of Laboratory Medicine and Pathology, Mayo Clinic, NIDDK NIH HHS.
Abstract (Originalsprache)
Background and Aims Inflammatory bowel disease (IBD) is associated with altered mucus and increased intestinal permeability (IP). Prior reports on permeability in IBD typically used lactulose-to-mannitol ratio (LMR). Food contamination with 12C-mannitol is a significant potential confounder in IP assessment. We aimed to compare small intestinal (SI) and colonic (COL) permeability in IBD, both active (ACT) and in remission (REM), to normal healthy volunteers (NHV).
Methods
Inflammatory bowel disease activity was based on Simple Endoscopic Score for Crohn’s Disease (SES-CD) and Mayo endoscopy score for ulcerative colitis (UC). We performed 24-hour IP test using 100 mg 13C-mannitol and 1000 mg lactulose with urine collected during 0-2, 2-8, and 8-24 hours. The primary endpoint was mg excretion of 13C-mannitol and lactulose during 2-24 hours reflecting SI and COL permeability.
Results
Among 17 CD patients, 7 were ACT (SES-CD >6), and 10 REM (SES-CD 0-2). Among 20 UC patients, 10 had ACT (Mayo score 2-3), and 10 REM (Mayo score 0-1). Urinary excretions over 2-24 hours were higher for IBD than NHV: 13C-mannitol (13.8 [IQR 8.8, 18.7] NHV; 18.4 [15.6, 29.9] REM; 19.7 [13.8, 23.6] ACT, P = .003) and lactulose (1.8 [1.3, 3.1] NHV; 3.6 [2.0, 5.0] REM; 3.5 [2.0, 6.6] ACT, P = .006). There was no difference between ACT and REM for any timed urine collection. LMR at 2-24 hours (or 2-8 and 8-24 hours) were not statistically significant between the 3 groups (0.014 [0.010, 0.021] NHV; 0.016 [0.010, 0.023] REM; 0.016 [0.012, 0.038] ACT, P = .237).
Conclusions
Intestinal permeability is increased in IBD using validated in vivo assay relative to NHV; increased IP in IBD persists during remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Katie A Dunleavy, Michael Camilleri
Förderung
- NIH HHS
- Department of Laboratory Medicine and Pathology, Mayo Clinic
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Dunleavy, K. A., Rypstra, C. R., Busciglio, I., Eckert, D., Ryks, M., Omerdic, E., Chedid, V. G., Raffals, L. E., & Camilleri, M. (2025). Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission. Inflammatory Bowel Diseases, 31(9), 2511-2520. https://doi.org/10.1093/ibd/izaf043
Vancouver
Dunleavy KA, Rypstra CR, Busciglio I, Eckert D, Ryks M, Omerdic E, et al. Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission. Inflammatory Bowel Diseases. 2025;31(9):2511-2520. doi:10.1093/ibd/izaf043
BibTeX
@article{Dunleavy2025,
author = {Dunleavy, Katie A and Rypstra, Chad R and Busciglio, Irene and Eckert, Deborah and Ryks, Michael and Omerdic, Ellie and Chedid, Victor G and Raffals, Laura E and Camilleri, Michael},
title = {Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {9},
pages = {2511--2520},
doi = {10.1093/ibd/izaf043}
}
EUVIMED